Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: Attrition rate and evolution of disease activity

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Vander Cruyssen, Bert ^a   Durez, Patrick ^b   Westhovens, Rene ^c   De Keyser, Filip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALOPECIA; ARTICLE; BACTERIAL ARTHRITIS; BREAST CANCER; CARDIOMYOPATHY; COLORECTAL CANCER; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PERICARDIAL EFFUSION; PLEURISY; POLYNEUROPATHY; REMISSION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SEPSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; BELGIUM; DISEASE COURSE; DRUG COMBINATION; HEALTH SURVEY; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BELGIUM; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951875709     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2997     Document Type: Article

References (17)

1. Lipsky PE, Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939. 10.1016/S0140-6736(99)05246-0, 10622295.
3. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007, 46:529-532. 10.1093/rheumatology/kel326, 17012439.
4. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
5. Heijde DM, van't Hof M, van Riel PL, Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581.
6. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
7. Durez P, Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005, 44:465-468. 10.1093/rheumatology/keh494, 15695306.
8. Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005, 7:R1063-1071. 10.1186/ar1787, 1257436, 16207323.
9. Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006, 8:R112. 10.1186/ar2001, 1779428, 16978395.
10. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005, 118:515-520. 10.1016/j.amjmed.2005.01.029, 15866254.
11. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006, 65:753-759. 10.1136/ard.2005.044404, 1798163, 16308341.
12. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8:R72. 10.1186/ar1941, 1526631, 16620398.
13. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, Ostergaard M, Tarp U. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008, 67:1023-1026. 10.1136/ard.2007.087262, 18272669.
14. Kievit W, Adang EM, Fransen J, Kuper HH, Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008, 67:1229-1234. 10.1136/ard.2007.083675, 18174220.
15. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005, 52:2616-2624. 10.1002/art.21259, 16142762.
16. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32. 10.1002/art.27227, 20039405.
17. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003, 62:944-951. 10.1136/ard.62.10.944, 1754333, 12972472.